Abstract
Significant advances in the areas of identification of disease susceptibility genes and gene transfer technologies have fueled new initiatives in cellular engineering as a means for treating metabolic disease. This article utilizes new findings from such work as the blueprint for a discussion of the prospects for gene therapy in diabetes mellitus.